月別アーカイブ: 2013年10月

Antares Pharma to Host Third Quarter 2013 Operating and Financial Results Conference Call

EWING, N.J.–(BUSINESS WIRE)–

Antares Pharma, Inc. (ATRS) today announced it will release its
third quarter 2013 financial results before the market opens on
Wednesday, November 6, 2013, and host a conference call shortly
thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul
K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F.
Apple, EVP, Chief Financial Officer, and President of the Parenteral
Products Division, will host the call.

Interested parties may participate in the conference call by dialing
1-800-762-8795 (US) or 1-480-629-9773 (international), 5-10 minutes
prior to the start of the call. A replay of the conference call will be
available approximately 2 hours after the call’s conclusion through
12:00 p.m. ET (Eastern Time) on November 20, 2013 by dialing
1-800-406-7325 (US) or 1-303-590-3030 (international), and entering the
access code 4647461. An audio web cast and archive of the conference
call will also be available under the investor relations section of the
Antares Web site at www.antarespharma.com.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical
products and topical gel-based medicines. The Company has received
marketing approval from the U.S. Food and Drug Administration for
OTREXUP™ (methotrexate) injection for the treatment of adults with
severe active rheumatoid arthritis, children with active polyarticular
juvenile idiopathic arthritis and adults with severe recalcitrant
psoriasis. Antares Pharma is also developing VIBEX® QS T for
testosterone replacement therapy. The Company’s technology platforms
include VIBEX® disposable Medi-Jet™, disposable multi-use pen
injectors and Vision™ reusable needle-free injectors marketed as Tjet®
and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva)
and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has
a multi-product deal with Teva that includes Tev-Tropin®
[somatropin (rDNA origin) for injection] human growth hormone (hGH),
VIBEX® epinephrine and several other products. Antares
Pharma’s partnership with Ferring includes Zomacton® hGH
(somatropin) injection. In the U.S. Antares has received FDA approval
for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder
that is marketed by Actavis. Elestrin® (estradiol gel) is FDA
approved for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause, and is marketed in the U.S. by Meda Pharma.
Antares Pharma has two facilities in the U.S. The Parenteral Products
Group located in Minneapolis, Minnesota directs the manufacturing and
marketing of the Company’s reusable needle-free injection devices and
related disposables, and develops its disposable pressure-assisted
Medi-Jet and pen injector systems. The Company’s corporate office and
Product Development and Commercial Groups are located in Ewing, New
Jersey.

Source Article from http://finance.yahoo.com/news/antares-pharma-host-third-quarter-110000991.html
Antares Pharma to Host Third Quarter 2013 Operating and Financial Results Conference Call
http://finance.yahoo.com/news/antares-pharma-host-third-quarter-110000991.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results



Former Maine pharmacist sentenced for drug thefts


PORTLAND, Maine (AP) — A former Maine pharmacist has been sentenced to 14 days in jail after pleading guilty to stealing prescription drugs at the hospital where he worked.

Attorney General Janet Mills says 60-year-old John Underwood of Bath pleaded guilty in Cumberland County Superior Court this month to two counts of stealing drugs in connection with a series of thefts of the opiate painkiller Oxycodone and sleep aid Ambien from Mid Coast Hospital in Brunswick. Mills says Underwood was the pharmacy manager for 32 years and was stealing the drugs for personal use.

The Maine Board of Pharmacy revoked Underwood’s license last year. According to his consent decree with the board, he stole a number of different drugs and ingested some of them while working.

Source Article from http://feeds.boston.com/c/35022/f/646951/s/331a2258/sc/40/l/0L0Sboston0N0Cnews0Clocal0Cmaine0C20A130C10A0C30A0Cformer0Emaine0Epharmacist0Esentenced0Efor0Edrug0Ethefts0C64Yc8aoQmMJgX9WyOG9HdN0Cstory0Bhtml/story01.htm
Former Maine pharmacist sentenced for drug thefts
http://feeds.boston.com/c/35022/f/646951/s/331a2258/sc/40/l/0L0Sboston0N0Cnews0Clocal0Cmaine0C20A130C10A0C30A0Cformer0Emaine0Epharmacist0Esentenced0Efor0Edrug0Ethefts0C64Yc8aoQmMJgX9WyOG9HdN0Cstory0Bhtml/story01.htm
http://news.search.yahoo.com/news/rss?p=pharmacist
pharmacist – Yahoo News Search Results
pharmacist – Yahoo News Search Results



Specialty Pharmacy Association of America Announces Two Additions to Board of Directors

ARLINGTON, VA–(Marketwired – Oct 30, 2013) – The Specialty Pharmacy Association of America (SPAARx), the largest national trade association representing the broad interests of the specialty pharmacy industry, today announced that Gaston Bernstein, President & CEO of Biomed Pharmaceuticals and Nuaman Tyyeb President/Managing Partner of CareMed Pharmaceutical Services, Inc. will join the SPAARx Board of Directors.

Mr. Bernstein has 25 years of experience in senior leadership positions in the healthcare industry. Prior to joining Biomed, Gaston served as Vice President of Industry Relations for Coram LLC, a national specialty infusion and specialty pharmacy provider. Before Coram, Gaston served as National Director of Managed Care for IVPCARE, a large Dallas-based specialty pharmacy company. Gaston has also held a variety of senior roles with various other specialty pharmacies, PBMs and pharmaceutical manufacturers.

Mr. Bernstein stated, “I look forward to participating and interacting with my esteemed colleagues on the SPAARx board while serving to help guide and grow the association in a meaningful and effective manner.” He further said, “The SPAARx trade association is the perfect vehicle for all of us to do our part in helping to advance the business and professional interest of the specialty pharmacy industry.”

Mr. Tyyeb brings his valued industry expertise that includes a wide range and depth of both financial and business skills. He has provided a number of years of leadership and support to both large and small healthcare companies. With an extensive background in finance, accounting and operations, Mr. Tyyeb offers a unique knowledge and expertise from both the provider and health plan side of healthcare delivery and reimbursement. Prior to his appointment as President and Managing Partner of CareMed Pharmaceutical Services, Nuaman served as its Chief Financial Officer in which he had responsibility and oversight of the firm’s finances, budgets, and all billing functions.

Mr. Tyyeb stated, “I am honored to participate and serve on the SPAARx Board. This is a large and growing national association that best represents the business and professional interests of the specialty pharmacy industry.” He added, “It has the most influential constituents and sponsors who can successfully petition specialty pharmacy as a distinct class of trade.”

The SPAARx Board of Directors and other SPAARx committee members, which include some of the industry’s most respected professionals, are working together to lead the specialty pharmacy industry by:

  • Establishing specific guidelines and standards for industry providers which includes recognizing the practice of specialty pharmacy as a separate class of trade;
  • Communicating the value of specialty pharmacy through effective channels of communication and forums;
  • Supporting the professional growth of our industry and its member organizations;
  • Protecting and promoting the interests of specialty pharmacy by fostering an advantageous business and political environment whereby members can achieve their business objectives;
  • Working with all of the constituents within the healthcare industry to overcome the challenges of the evolving specialty pharmacy marketplace.

Kevin Alder, Chief Operating Officer for SPAARx, noted, “We are fortunate to have attracted this well-versed group from within specialty pharmacy.” Alder went on to say, “As the foremost trade association representing the specialty pharmacy industry, the SPAARx Board has the essential strategic vision needed to guide the association on matters of importance to the industry.” He added, “We welcome the addition of both Mr. Bernstein and Mr. Tyyeb to the SPAARx Board and look forward to their valued contributions.”

About SPAARx
The Specialty Pharmacy Association of America (SPAARx) is the nation’s leading free-standing, national trade association, representing the interests of the specialty pharmacy industry. SPAARx is an industry neutral, mission driven organization that is governed by an independent Board of Directors comprised of senior executives from a diverse group of specialty pharmacies. SPAARx works to establish guidelines and standards to differentiate specialty pharmacy within the industry. SPAARx is also the leading advocate for important legislative and regulatory issues that may impact all specialty pharmacies nationally while helping to advance the professional and personal development of those working in specialty pharmacy settings. www.spaarx.org

SPAARx
Kevin Alder
Chief Operating Officer
Specialty Pharmacy Association of America (SPAARx)
4601 North Fairfax Drive; Suite 1200
Arlington, VA 22203

Office: 973.295.3293
Email: kevin.alder@spaarx.org

Source Article from http://finance.yahoo.com/news/specialty-pharmacy-association-america-announces-123000303.html
Specialty Pharmacy Association of America Announces Two Additions to Board of Directors
http://finance.yahoo.com/news/specialty-pharmacy-association-america-announces-123000303.html
http://news.search.yahoo.com/news/rss?p=pharmacy
pharmacy – Yahoo News Search Results
pharmacy – Yahoo News Search Results